Boston, MA 06/11/2014 (wallstreetpr) – Northwest BioTherapeutics, Inc (NASDAQ:NWBO) reported significantly positive results in its Phase I/II clinical trial involving DCVax-Direct to treat various kinds of inoperable solid tumors.
Trial Results
The biotechnology company announced observing successful results in all 9 patients who were treated with 4 out of the 6 intended injections. The tumors in these patients have been observed to either completely die or to significantly shrink. Also, a substantial accumulation of immune cells was observed in the tumors of all 9 patients, along with an observable stabilization of cancer advancement. Additionally, 3 of the 9 treated patients show complete eradication of live tumor cells when biopsies were conducted and live tumor cells were injected.
So far, 20 people have been injected thrice out of the 6 intended injections, of which 13 have demonstrated tumor cell death, shrinkage, significant immune cells accumulation in tumors, and/or steady disease condition. The first 3 injections are administered within 2 weeks of the entire therapy regime which extends to 32 weeks.
Special Cases
Until now, only 9 patients, those referenced above, have been administered 4 out of 6 injections. The patients receive the fourth injection in the eighth week of the 32 week long therapy regime. The treatment demand injecting the dosages in the following sequence: on the first day, on the eighth day, on the fifteenth day that is the first day of the second week, followed by injections in weeks 8, 16 and the last one in the 32nd week of the therapy regime.
Additionally, in the study which required conducting biopsies on 3 of the 9 aforesaid patients, results showed absence of any live tumor cells in an injected tumor. The 3 candidates who were chosen for the trial suffered from advanced and aggressive cancers of diverse types. The cases were: metastatic sarcoma; metastatic colon cancer; and metastatic pancreatic cancer.
The Northwest BioTherapeutics, Inc (NASDAQ:NWBO) seeks to give a detailed report as the patients receive further treatment.
